Jaspal Arora, MD
Family Medicine · Milwaukee, WINPI 1699783282
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $580 and has fallen 78.3% since, to $126 in 2025.
Across 42 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$162
- Boehringer Ingelheim$91
- Convatec Inc.$89
- GSK$79
- Lilly USA, LLC$69
- Novo Nordisk$61
- plus $352 from 11 others
What the payments were for
- Food & beverage$88398%
- Education$212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $162 |
| Boehringer Ingelheim | 5 | $91 |
| Convatec Inc. | 1 | $89 |
| GSK | 4 | $79 |
| Lilly USA, LLC | 4 | $69 |
| Novo Nordisk | 4 | $61 |
| Bayer | 2 | $58 |
| Almatica Pharma LLC | 2 | $50 |
| VBI Vaccine (delaware) Inc. | 2 | $38 |
| Exact Sciences | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $31 |
| Pfizer | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $26 |
| OPKO Pharmaceuticals, LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Amgen | 1 | $13 |
How this compares
$904 in reported general payments places this provider in the 85th percentile of 1,482 family medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $100,181 |
| FarxigaDapagliflozin Propanediol | 56 | $50,706 |
| JardianceEmpagliflozin | 28 | $44,244 |
| OzempicSemaglutide | 30 | $41,763 |
| TrulicityDulaglutide | 20 | $29,907 |
| LinzessLinaclotide | 35 | $29,368 |
| JanuviaSitagliptin Phosphate | 25 | $23,455 |
| MyrbetriqMirabegron | 23 | $21,573 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $16,539 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $13,403 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,840 |
| Praluent PenAlirocumab | 15 | $6,878 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,038 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $5,261 |
| Atorvastatin Calcium | 477 | $4,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $31 | $100,18188 claims |
| AstraZenecaFarxiga, Symbicort | $162 | $58,54677 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $91 | $50,28240 claims |
| Novo NordiskOzempic | $61 | $41,76330 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $79 | $29,94237 claims |
| Lilly USA, LLCTrulicity | $69 | $29,90720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,482 family medicine providers in Wisconsin.
Other family medicine in Milwaukee
- William PalinMilwaukee$693K
- Steven BondowMilwaukee$34K
- Suresh MisraMilwaukee$16K
- Ramneet BhathalMilwaukee$12K
- Roland WillockMilwaukee$7K
- Arthur MinesMilwaukee$6K
- Jennifer ParsleyElk Mound$1.4M
- Ryan AndrewsStevens Point$429K
- Tara DallDelafield$230K
- Mark JensonGreen Bay$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.